TAMARA HALBERSMA: Open Payments
NPI 1548859374 · DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$939 in 49 payments from 15 companies in 2025. Trend: 2023 $155 · 2024 $594 · 2025 $939
Food & beverage: $939
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $224 |
| Alkermes, Inc. | 14 | $203 |
| ABBVIE INC. | 4 | $74 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $70 |
| Almatica Pharma LLC | 3 | $62 |
| Janssen Pharmaceuticals, Inc | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, FANAPT, LOREEV XR, REXULTI, SPRAVATO, AUSTEDO XR.
Industry payments across IA — which companies pay providers there.
